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In pemphigus vulgaris, treatment with systemic glu-
cocorticosteroids is life saving; it may, however, cause
severe side e¡ects, including death. A patient with pem-
phigus vulgaris and myasthenia gravis was treated for
approximately ¢ve years with the cholinomimetic
Mestinon (pyridostigmine bromide), Imuran (azathio-
prine), and a topical corticosteroid gel before the need
to introduce systemic glucocorticosteroids. Because
activation of keratinocyte acetylcholine receptors also
has been shown to abolish pemphigus IgG^induced
acantholysis in cultured keratinocyte monolayers, a
clinical trial of Mestinon was initiated in patients with
active pemphigus vulgaris, pemphigus foliaceus, and
paraneoplastic autoimmune multiorgan syndrome (also
known as paraneoplastic pemphigus). First results indi-
cate that nonsteroidal treatment of pemphigus is possi-
ble. Mestinon may be used to slow down progression of
the disease and to treat mild cases with chronic lesions
on limited areas. Stimulation of the keratinocyte^ acet-
ylcholine axis may lead to a therapeutic e¡ect through
any of the following mechanisms: (1) stimulating kera-
tinocyte cell-to-cell attachment; (2) accelerating re-
epithelialization; and (3) competing with the disease-
causing pemphigus antibodies, preventing them from
attachment to keratinocytes. Glucocorticosteroids and
various types of steroid-sparing drugs used to treat
pemphigus exhibit cholinergic side e¡ects, including
e¡ects on expression and function of keratinocyte adhe-
sion molecules, that are very similar to those produced
by the cholinomimetic drugs. Further elucidation of the
mechanisms underlying therapeutic e⁄cacy of antia-
cantholytics may shed light on the immunopharmaco-
logical mechanisms of pemphigus antibody^induced
acantholysis. Key words: acantholysis/acetylcholine receptor/
keratinocyte/Mestinon/myasthenia gravis/pemphigus vulgaris.
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T
hemajor objective of pemphigus research is develop-
ment of a safer treatment regimen. Pemphigus pa-
tients need drugs that can replace the gluco-
corticosteroid hormones (GS) that many of them
must take for life. GS therapy is life saving, but
patients su¡er from severe side e¡ects and complications. Alterna-
tive therapies that foster keratinocyte adhesion and/or speci¢cally
antagonize the e¡ects of pemphigus antibodies are desperately
needed. In the past, I developed treatment modalities (Grando,
1988; Grando et al, 1989d; Grando et al, 1990; Grando, 1992) that,
in addition to GS, included: (1) ex-vivo ¢ltration of patients’ blood
through carbon adsorbent, followed by plasmapheresis and ad-
ministration of cytostatic drugs, to eliminate disease-causing
pemphigus autoantibodies and suppress the synthesis of new
ones; (2) antiproteases, antikinins, and antileukotrienes (querce-
tin, aprotinin, and e-aminocaproic acid) to inactivate mediators
of in£ammation present in pemphigus blister £uid (Grando et al,
1987; Grando et al, 1989a; Grando et al, 1989c); and (3) doxycycline
to suppress the cell-mediated autoimmunity component of pem-
phigus’ immunopathogenesis (Grando et al, 1989b). Unfortunately,
none of these approaches allowed complete replacement of GS in
pemphigus patients. Recent research results, however, suggest
that novel antiacantholytic therapies may be developed by mi-
micking the antiacantholytic e¡ects of GS with nonsteroidal
drugs acting at the acetylcholine receptors (AChR) expressed by
keratinocytes (Grando et al, 2001). Keratinocyte adhesion is con-
trolled, in part, by acetylcholine (ACh), a cytokine-like chemical
(i.e., a cytotransmitter) that is locally produced by keratinocytes
(reviewed in Grando, 1997). ACh and its congeners (i.e., cholino-
mimetic drugs) can reverse pemphigus antibody^induced
acantholysis both in vitro (Grando and Dahl, 1993) and in vivo.1
Taking into consideration that GS can prevent but not reverse
pemphigus IgG-induced acantholysis (Swanson and Dahl, 1983),
these observations suggest that cholinomimetic drugs might be a
novel and more e⁄cient treatment for pemphigus. A case of pem-
phigus vulgaris (PV) that improved by cigarette smoking (Mehta
and Martin, 2000), studies showing negative correlation between
smoking and pemphigus (Brenner et al, 2001), and successful use
of nicotinamide as a steroid-sparing agent in pemphigus (Chaf-
¢ns et al, 1993) hint that this expectation is realistic for the follow-
ing reasons: (1) cigarette smoke contains cholinomimetic
nicotine; and (2) nicotinamide exhibits cholinomimetic e¡ects
(Romanenko, 1987) due to both stimulation of ACh release
(Koeppen et al, 1997) and inhibition of acetylcholinesterase
(AChE) (Stoytcheva and Zlatev, 1996). The rationale behind the
use of cholinergic drugs also stems from data demonstrating in-
volvement of keratinocyte AChR in pemphigus pathophysiology
(reviewed in Grando, 2000). On these premises, I hypothesized
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that cholinomimetics should abort or alleviate pemphigus. This
therapeutic approach should be successful even if keratinocyte
AChR are not targeted by disease-causing pemphigus antibodies
in a particular patient, because ACh and its muscarinic and nico-
tinic congeners can accelerate the rate of keratinocyte migration,
thus fostering re-epithelialization of pemphigus erosions
(Grando, 1997). As a test of this hypothesis, an open clinical trial
of a nontoxic AChE inhibitor, Mestinon (pyridostigmine bro-
mide), was initiated approximately two years ago in the derma-
tology clinic of the University of California at Davis. In the
clinical trial, Mestinon was chosen as a systemic cholinomimetic
drug because an index patient with both PV and myasthenia
gravis (MG) had successfully treated her pemphigus for almost
¢ve years, without using systemic GS, by manipulating her daily
dose of Mestinon from 180 to 360 mg, taking Imuran (azathiopr-
ine) and applying a glucocorticoid gel to fresh lesions.
RESULTS
The results of the clinical trial reported herein were obtained in
eight patients with active pemphigus without MG, including all
three major clinical forms of autoimmune pemphigus. The diag-
nosis of pemphigus was based on the results of comprehensive
clinical and histological examinations, together with immunolo-
gical studies, following standard protocols (Beutner et al, 1985).
This study had been approved by the University of California,
Davis, Human Subjects Review Committee.
Treatment of PV without systemic GS in the index
patient The index patient was a 39-year-old Ashkenazi Jewish
female with both PV and MG. At the age of 18, she developed
arthralgias and was given the diagnosis of lupus erythematosus
on the basis of positive results of ANA, nDNA and VDRL
antibody tests and LE cell preparations. She was treated with
NSAIDs until the symptoms resolved by the age of 20 and the
above tests became normal. After that, she had two pregnancies
that resulted in miscarriages during the ¢rst trimester due to
large subchorionic hemorrhages associated with borderline titers
of anticardiolipin antibodies. A third pregnancy was complicated
by another large subchorionic hemorrhage in the ¢rst trimester,
but the pregnancy continued and resulted in a normal vaginal
delivery by induction. At the age of 30, she developed symp-
toms of nasal speech at ¢ve months into the next pregnancy.
Three weeks prior to delivery of the second child, she developed
ptosis of the left eyelid. Three days after delivery, her speech
became much more slurred and she developed di⁄culty in deep
breathing. The ¢nding of an anti-AChR antibody at the titer of
25 and the results of a Tensilon test con¢rmed the clinical diag-
nosis of MG. A chest CTscan revealed a hyperplastic thymus, but
was negative for thymoma. She was started on 60 mg Mestinon
three times a day. Initial improvement was followed by an in-
crease of muscular weakness, di⁄culty swallowing, and worsen-
ing of slurred speech. At the age of 31, she had a thymectomy,
which was preceded by ¢ve sessions of plasmapheresis. The
postoperative course was relatively uncomplicated. Since then,
she has been controlling her myasthenia symptoms with daily
doses of Mestinon ranging between 120 and 210 mg.
At the age of 33, this patient developed the initial symptoms of
PV. She ¢rst noticed occasional bleeding and in£ammation of her
gums that did not disturb her much. Approximately one year
later, multiple white and ulcerated areas on gingival crest and
crevice, which bled readily, were found during an annual dental
checkup. Super¢cial mucosa could be wiped away, indicating the
presence of a positive direct Nikolskiy sign (Grando et al, 2003). A
crusted erosion of approximately 11 cm that bled easily upon
mechanical stimulation was also found behind the right ear. She
was referred to an oral surgeon, who made an incisional biopsy of
the right posterior mandibular alveolar mucosa. The histopa-
thological study revealed suprabasilar acantholysis consistent
with PV. This clinical and histological diagnosis was con¢rmed
by the results of immunological studies performed at the
Beutner Laboratories (Bu¡alo, New York) during exacerbation
of her skin disease. Intercellular antibodies were found in the
perilesional skin by direct immuno£uorescence, and low-titer
intercellular antibodies were demonstrated by indirect
immuno£uorescence.
During the ¢rst four years, the course of PV in this patient was
rather mild. One to two new lesions on oral mucosa and/or skin
would develop monthly and heal quickly, either spontaneously or
upon the use of topical GS. These symptoms developed in the
background of a maintenance dose of Mestinon. At the age of
37, the patient developed a moderately severe exacerbation
characterized by the appearance of approximately 50 small, 1^2-
cm-diameter, bullous lesions on skin and oral mucosa soon after
these preceding events: (1) ¢ve sessions of intravenous gamma-
globulin injections over a period of one week in an attempt to
improve myasthenia symptoms; (2) slight tapering of Mestinon
because improvement of myasthenia had been achieved; and (3)
severe emotional stress. Systemic GS were not initiated because
of the threat of a myasthenic crisis. Instead, the patient was
treated with plasmapheresis. For several years after that, in
addition to the maintenance dose of Mestinon, she took Imuran
at a daily dose of 150 mg and used 0.05% clobetasol propionate
gel (Temovate) on new pemphigus lesions that occasionally
appeared on her skin and oral mucosa. Her pemphigus antibody
titer remained at 1/320, as determined by indirect immuno-
£uorescence using monkey esophagus as a substrate. She
infrequently developed side e¡ects from the Mestinon, such as
skin £ushes, sweating, and diarrhea. Otherwise, she had a good
quality of life. After approximately ¢ve years of treatment, the
lesions on her skin and oral mucosa began to develop more
frequently, which required initiation of prednisone therapy to
control her PV. Currently, she takes 20 mg prednisone per day.
First results of clinical trial of mestinon in pemphigus
patients The intriguing aspect of the management of the index
patient was that conventional GS therapy was not instituted for the
¢rst ¢ve years of her disease. Although it is possible to maintain
pemphigus patients in remission using immunosuppressive drugs
without GS (Lever and Schaumburg-Lever, 1977; Lever and
Schaumburg-Lever, 1984; Stemm and Thivolet, 1995), initial
treatment of PV relies on systemic GS in a high dose (Holubar
and Fellner, 1986; Muller and Stanley, 1990; Carson et al, 1996). To
the best of my knowledge, neither Imuran alone nor Imuran in
combination with plasmapheresis and/or Temovate gel has ever
been reported to allow complete avoidance of systemic GS at the
initial stage of pemphigus treatment. Therefore, I considered
Mestinon as a therapeutic agent that ameliorated the natural
course of disease in this patient, and I initiated an open clinical
trial. An overall goal was to evaluate the e⁄cacy of Mestinon in
terminating the spread of pemphigus erosion and in fostering re-
epithelialization of already existing lesions. Both new patients with
pemphigus who had not received GS and established patients with
disease exacerbation on the background of immunosuppressive
therapy were enrolled. Patients with generalized, life-threatening
forms of disease whose well being might be jeopardized by any
delay in initiating systemic GS therapy were excluded from the
study, as were children less then than 16 years of age, pregnant
women, and nursing mothers.
During approximately two years of the clinical trial, eight
patients with active pemphigus used Mestinon for at least four
weeks (Table 1). They took Mestinon tablets at a total daily dose
of 360 mg. Three PV patients (patients 1, 6, and 8) and a patient
with paraneoplastic autoimmune multiorgan syndrome [(PAMS;
also known as paraneoplastic pemphigus (Nguyen et al, 2001)]
showed a very good response (the patients are hereafter referred
to as the responders). The other three PV patients and one
pemphigus foliaceus patient showed no signi¢cant improve-
ment. Among the responders, two PV patients (patients 1 and 6)
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and the PAMS patient were able to control their disease using
Mestinon alone. One responder demonstrated a direct strong
interrelationship between the use of Mestinon and the ability to
control his PV (patient 1; Fig 1). After achieving stable control, he
discontinued Mestinon. Approximately two weeks later, he
reported redness and itching/burning sensations at the sites of the
fully healed pre-existing lesions, which were followed by
microvesiculation and advert lesional weeping. At this point,
Mestinon was restarted. Within several days, the progression of
the lesions aborted and the erosions began to dry. It took about
three weeks for the lesions to completely heal, after which the
patient slowly tapered his Mestinon daily dose to zero. He has
remained free from lesions for almost 18 months without any
need of medication for pemphigus. This patient provides a ‘‘proof
of concept’’case of the e⁄cacy of Mestinon in pemphigus because
he showed (1) rapid improvement of his disease at the time the
drug was taken, although this might be attributed to a
coincidental spontaneous improvement of the disease; (2) rapid
exacerbation of PV after the drug had been abruptly
discontinued; and (3) rapid reversal of the £are-up of his PV after
the drug had been restarted.
DISCUSSION
Possible mechanisms of the therapeutic e⁄cacy of Mestinon
in pemphigus The ¢rst results of the clinical trial of Mestinon
are encouraging, indicating that this cholinomimetic can be used
to slow down progression of disease in patients with acute
pemphigus and to treat mild cases with limited areas of
nonhealing erosions. No controls needed to be allocated to
standard therapy because the success of the new treatment could
be judged against the well-known standard prognosis. The course
of pemphigus is well characterized, and it is well known that
practically all pemphigus patients relapse if systemic GS are
withdrawn during the disease’s active phase (Herbst and
Bystryn, 2000). In a classic example, Dr. Morton established the
e⁄cacy of anesthesia by demonstrating that one anesthetized
patient felt none of the excruciating pain that had invariably
accompanied surgery. Therefore, the ‘‘proof of concept’’ result
with Mestinon in the PV patient shown in Fig 1 indicates that
an approach to the treatment of pemphigus that employs
cholinomimetics is practical. The obtained results do raise a
question, however: How can Mestinon suppress acantholysis in
pemphigus? The answer may provide a new lead in solving the
pemphigus enigma.
It is well known that Mestinon increases tissue levels of
endogenous ACh because of the reversible inhibition of AChE
that hydrolyzes ACh (Taylor, 1985). Keratinocytes actively
metabolize ACh, employing the synthesizing enzyme choline
acetyltransferase (ChAT) and the degrading enzyme AChE, and
they use ACh as an autocrine and paracrine hormone or
cytotransmitter (reviewed in Grando, 1997). Additionally,
Mestinon can act directly on keratinocyte AChR because it has
Table1. Summary of the Results of Open Trial of Mestinon in Pemphigus Patientsa
Patient Age/Sex Diagnosis IF tests
Nikolskiy
sign
Prior systemic
therapy
Systemic treatment
during the trial Outcome of the trial
Systemic treatment
after the trial
1 45/M PV positive positive GS , IS none permanent remission taper Mestinon over 3 months
2 64/F PV positive positive GS, IS GS no improvement GS , IS
3 38/M PV positive positive GS, IS GS (lower dose) no improvement GS, IS
4 33/M PF ND positive GS GS (lower dose) no improvement GS, IS
5 65/M PAMS positive negative GS, IS none temporary remission GS (lower dose); Mestinon
6 53/F PV positive positive none none improvement Mestinon
7 51/F PV positive positive GS, IS GS, IS no improvement GS , IS
8 82/M PV positive ND GS, IS GS (lower dose) improvement GS (lower dose); Mestinon
aAbbreviations: GS, glucocorticosteroid hormones; IF, direct and/or indirect immuno£uorescence; IS, immunosuppressors; ND, not done; PAMS, paraneoplastic auto-
immune multiorgan syndrome; PF, pemphigus foliaceus; PV, pemphigus vulgaris.
Figure1. Treatment of Pemphigus Vulgaris
with Mestinon. (A) Before treatment. (B) Three
months on Mestinon. (C) Three weeks after dis-
continuing Mestinon. (D) One month after restart-
ing Mestinon.
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been shown to interact directly with cholinergic receptors as a
weak agonist capable of inducing desensitization, both alone and
when combined with ACh (Akaike et al, 1984). Human epidermal
keratinocytes express both the ACh-gated ion channelsthat is,
the neuronal-type nicotinic AChR (nAChR), which can
comprise a3, a5, a7, a9, a10, b2, and b4 subunits (Grando et al,
1995a; Grando et al, 1996; Nguyen et al, 2000a; Nguyen et al,
2000b; Sgard et al, 2002)and G protein^coupled muscarinic
AChR (mAChR) of the M1, M3, M4, and M5 subtypes (Ndoye
et al, 1998). Oral keratinocytes also express the M2 mAChR
subtype, but lack M1 (Arredondo et al, 2003). Mestinon can
interact with the ACh-ionic channel complex, blocking it in
open conformation, via at least three distinct, although possibly
interacting, mechanisms: (1) a weak agonist action; (2) the
formation of desensitized receptor-complex intermediates; and
(3) the alteration of the conductance properties of active
channels (Albuquerque et al, 1984; Pascuzzo et al, 1984).
As will be detailed below, stimulation of the keratinocyte
ACh axis with Mestinon might lead to a therapeutic e¡ect in
pemphigus through any one or a combination of the following
mechanisms: (1) stimulating keratinocyte cell-to-cell attachment;
(2) promoting faster re-epithelialization; and (3) competing with
the disease-causing pemphigus antibodies, preventing them from
attachment to keratinocyte AChR.
ACh as a cytotransmitter regulating keratinocyte adhesion
Mestinon might intercede at the intracellular signaling pathway
that mediates the acantholytic e¡ects of pemphigus antibodies. The
binding of pemphigus IgG to keratinocytes leads to acantholysis
through activation of a biochemical cascade that involves activation
of phospholipase C, production of inositol 1,4,5-trisphosphate, Ca2þ
in£ux and rapid transient increase of intracellular Ca2þ , changes in
the intracellular cAMP/cGMP ratios, and activation and translo-
cation of protein kinase C from the cytosol to the particulate/
cytoskeleton fractions (Grando et al, 1988; Esaki et al, 1995;
Lyubimov et al, 1995; Seishima et al, 1995; Osada et al, 1997). The
other messenger systems used by ACh are the same as those used
by pemphigus IgG (Grando et al, 1988; Esaki et al, 1995; Lyubimov
et al, 1995; Seishima et al, 1995; Osada et al, 1997). In e¡ect, activation
of keratinocyte AChR restores normal morphology of pemphigus
IgG^treated acantholytic keratinocytes in cultures (Grando and
Dahl, 1993). Therefore, a signal sent by ACh through activating
keratinocyte AChR can override the signal evoked by pemphigus
antibody binding to keratinocytes.
It has been convincingly demonstrated that nicotinic and
muscarinic drugs exhibit dramatic e¡ects on cell-to-cell and cell-
to-substrate cohesion of human epidermal and oral keratinocytes
(Grando and Dahl, 1993; Grando et al, 1993; Grando et al, 1995a;
Nguyen et al, 2000a; Nguyen et al, 2000b). Blocking AChR with
either muscarinic or nicotinic antagonistsatropine and
mecamylamine, respectivelyin both cases results in acantholysis
in keratinocyte monolayers (Grando and Dahl, 1993; Grando et al,
1995a). Notably, systemic use of atropine has exacerbated skin and
oral blistering in one of our patients with PV. Results obtained in
our pilot studies strongly suggest that cholinergic control of
keratinocyte adhesion is exerted through receptor-mediated
modi¢cations of both expression and phosphorylation of adhesion
molecules.2 For instance, we demonstrated that the acantholytic
e¡ect of atropine is associated with increased phosphorylation of
cadherins in DJM-1 cell monolayers. Phosphorylation of classical
and desmosomal cadherins is known to be involved in regulation
of cell-to-cell adhesion (Parrish et al, 1990; Stappenbeck et al, 1994;
Pasdar et al, 1995; Kowalczyk et al, 1999), and pemphigus IgG^
induced acantholysis involves phosphorylation of desmoglein 3 and
its dissociation from plakoglobin (Aoyama et al, 1999). Interestingly,
ligation of a9 AChR has been reported to induce phosphorylation
of cell membrane proteins with molecular weights of 120 and 220
kDa (Szonyi et al, 1999). These may represent adhesion molecules,
such as the 120-kDa E-cadherin (Mareel et al, 1991) and the 220-
kDa desmoplakin 2 (Joly et al, 1994). Thus, Mestinon might
stimulate keratinocyte adhesion by activating classical and
desmosomal cadherins, including e¡ects on the phosphorylation
status of an adhesion molecule.
ACh as a cytotransmitter regulating re-epithelialization
Re-epithelialization of pemphigus erosions is a self-sustained
process that can be regulated by endogenously secreted media-
tors such as ACh. ACh can facilitate keratinocyte outgrowth in
culture. Both muscarinic and nicotinic agonists produce a
stimulatory e¡ect on keratinocyte spreading and migration,
whereas inhibiting ACh synthesis and blocking AChR abrogate
lateral migration of human keratinocytes (Grando et al, 1993;
Grando et al, 1995a). In neurons, too, ACh regulates the direction
of nerve growth cone extension, and blocking ACh signaling
inhibits nerve outgrowth (Zheng et al, 1994). To characterize
cholinergic control of the metamorphosis of keratinocytes
during wound healing, we developed an in vitro model of skin
re-epithelialization that allows accurate evaluation of drug e¡ects
on lateral migration of keratinocytes (Grando et al, 1993).The cells
exposed to carbachol, a muscarinic and nicotinic agonist and
reversible AChE inhibitor, moved signi¢cantly farther compared
to nonexposed keratinocytes.3 The response to carbachol was
dose dependent and was seen starting from the nanomolar con-
centrations of the drug. Both the nicotinic antagonist mecamy-
lamine and the muscarinic antagonist atropine abrogated the
carbachol-induced keratinocyte migration. Recent results
obtained in in vivo skin-wounding experiments in AChR
knockout mice indicate that M4 mAChR plays a central role in
mediating cholinergic control of keratinocyte migration by
regulating integrin expression.4 Therefore, the role of Mestinon
as a stimulator of a basic regulatory pathway of keratinocyte
migration that might help re-epithelialize pemphigus erosions
merits further consideration.
Figure 2. Hypothetical plan of treatment
of pemphigus in the post-corticosteroid
era.
2Grando SA, Arredondo J, ChernyavskyA, KitajimaY, NguyenVT: Me-
chanisms of pharmacologic regulation of keratinocyte adhesion by choli-
nergic drugs. J Invest Dermatol 119:225, abstr. #107, 2002
3LeeTX, Horton RM, Grando SA: Cholinergic drugs stimulate chemo-
kinesis of human epidermal keratinocytes. J Invest Dermatol 106:841, abstr.
#215, 1996
4Chernyavsky A, Arredondo J, Nguyen VT, Ndoye A, Zia S, Wess J,
Grando SA: Molecular mechanisms of stimulatory e¡ect of M4 muscarinic
acetylcholine receptor on keratinocyte migration. J Invest Dermatol 119:225,
abtsr. #108, 2002
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Immunopathological similarities of PV and MG Although
experimental PV in neonatal mice can be induced with
autoantibodies to the adhesion molecules desmoglein 1 and
desmoglein 3 (Amagai et al, 1992; Arteaga et al, 2002), results
obtained in my laboratory show that pemphigus symptoms can
be induced in neonatal mice lacking desmoglein 3 with passive
transfer of the PV IgG that lack desmoglein 1 antibody (Nguyen
et al, 1998). The pool of disease-causing pemphigus antibodies
includes the autoantibodies to keratinocyte AChR, which are
found in approximately 85% of patients (Nguyen et al, 1998).
The antigenic speci¢cities of pemphigus antibodies include the
novel human a AChR (Nguyen et al, 2000b), with mixed,
nicotinic and muscarinic pharmacology (Elgoyhen et al, 1994),
and pemphaxin, a human annexin that binds ACh (Nguyen
et al, 2000c). Indeed, pemphigus antibodies have been shown to
compete directly with a cholinergic radioligand, [3H]atropine,
for binding to keratinocytes (Grando and Dahl, 1993), indicating
that binding of anti-AChR IgG to keratinocytes can produce an
immunopharmacological e¡ect.
We reported a pemphigus patient with MG who developed an
autoantibody binding to keratinocyte a3 nAChR.5 Myasthenia
and pemphigus may therefore share a common immuno-
pathological pathway. MG is caused by autoantibodies against
the nAChR expressed at the neuromuscular junction to mediate
neuromuscular transmission (reviewed in Conti-Tronconi et al,
1994). These antibodies are heterogeneous and can be detected in
approximately 85% of patients (Tzartos et al, 1982). It is not
uncommon to ¢nd in some myasthenic patients clinical
manifestations of pemphigus (reviewed in Kaplan and Callen,
1983). In such patients, autoantibodies can be directed against
both desmosomal and neuromuscular antigens (McKee et al,
1978; Beutner et al, 2002). Likewise, AChR accumulate at both
desmosomal and neuromuscular junctions (Engel et al, 1977;
Grando et al, 1995b). Recently, Dr. Beutner’s group proposed that
in pemphigus associated with malignancies, autoimmunity may
serve primarily as a defense mechanism against such systemic
complications, although some forms of it, such as the
autoantibodies to AChR, can cause the death of patients with
PAMS (Beutner et al, 2002). Approximately 70% of MG patients
have thymitis, and approximately 10% develop thymoma
(reviewed in Marx et al, 1992). Like myasthenia, pemphigus may
be associated with a tumor of the thymus, and pemphigus,
thymoma, and myasthenia may coexist in the same patient
(reviewed in Younus and Ahmed, 1990; Sherer et al, 1997). This
raises the possibility that two seemingly disparate clinical
conditions such as PV and MG may have similar immuno-
pathological mechanisms. In addition to mAChR (Maslinski
Table 2. Cholinergic ‘‘Side-e¡ects’’ of Drugs Used to Treat Pemphigus
GS Via their genomic e¡ects, GS upregulate the cholinergic enzymes ChATand AChE (Kaufman et al, 1988) [although this e¡ect may vary
depending on the cell type (Tria et al, 1992; Hortnagl et al, 1993)] and increase expression of both nAChRs and mAChRs (Ben-
Baruch et al, 1981; Marquardt et al, 1982; Braun et al, 1993), which is proposed as a possible explanation for some of their therapeutic
e¡ects (Vilquin et al, 1992).The non-genomic e¡ects of GS are mediated by virtue of their ability to attach in a non-competitive manner
to a site of ACh-gated ion channels on the outer cell membrane and alter ACh-induced inward currents (Inoue and Kuriyama, 1989;
Bouzat and Barrantes, 1993; Ke and Lukas, 1996; Nurowska and Ruzzier, 1996).
Cyclophosphamide Behaves like a classic nicotinic cholinergic ligand, because it speci¢cally binds to the ligand-binding sites of both the muscle- and the
neuronal-types nAChRs (Minker and Blazso, 1987), but not mAChR (Peroutka, 1987), and also reversibly inhibits AChE activity in a
dose-dependent manner (al-Jafari et al, 1995).
Cyclosporin Augments synthesis of ACh (Esqui¢no et al, 1997), and also interferes with protein kinase C-mediated signal transduction from
mAChR (Hoecker et al, 1994).
Gold Aurano¢n and other gold-containing compounds inhibit ACh-mediated e¡ects on non-neuronal cells (Ohlstein and Horohonich,
1989; Fontaine et al, 1991).
Nicotinamide Increases tissue levels of choline [a metabolic precursor of ACh and pharmacologic agonist of AChRs [Sterz, 1986; Ulus, 1988]],
leading to increased ACh release (Koeppen et al, 1996; Koeppen et al, 1997), and also regulates mAChR-coupled Kþ channel
(Higashida et al, 1995; Higashida et al, 1996). Nicotinic acid (syn: niacin) acts as a competive inhibitor of AChE (Stoytcheva and Zlatev,
1996), whereas its ester exhibits an ACh-like e¡ect on smooth muscle contraction (Winkelman et al, 1969).
Tetracyclines Tetracycline, chlortetracycline, minocycline and doxycycline cause a concentration-dependent inhibition of ACh release (Anadon
and Martinez-Larranaga, 1987).
Tranilast Inhibits cholinergic neurotransmissions of guinea pig bronchial muscle in vitro (Kamikawa, 1989).
Aprotinin Inhibits activity of AChE (Chasapakis et al, 1968)the enzyme that hydrolyses not onlyACh but also various peptides, just like a
professional trypsin-like endopeptidase (Small et al, 1987).
Quercetin Inhibits ACh release (Lutterodt, 1989).
Heparin Enhances agonist binding to an inhibitory-type of mAChRs, due to disruption of the mAChR-G protein interactions (Wang et al,
1996), interferes with intracellular signalling from the stimulatory-type mAChR, due to inhibition of inositol 1,4,5-trisphosphate
(Olianas and Onali, 1997), and also inhibits AChR aggregation (Hopf and Hoch, 1997) and solubilizes AChE from the cell
membrane (Talesa et al, 1993).
Suramin Competitive agonist of nAChRs (Henning et al, 1992).
Quinine Causes a closed-channel block of nAChR (Ssieb et al, 1996), inhibits mAChR-induced Kþ currents (Chen et al, 1993), and also acts as
both non-competitive inhibitor of AChE (Stoytcheva and Zlatev, 1996) and a high a⁄nity competitive inhibitor of choline transport
(Porter et al, 1992).
Strychnine Speci¢c pharmacologic ligand of the novel a AChR that was ¢rst found in rat (Elgoyhen et al, 1994), and then cloned by us from
human keratinocytes (Nguyen et al, 2000b).
Arsenic compounds Inhibit mAChRs (Fonseca et al, 1991) and both cholinergic enzymes, ChAT and AChE (Kobayashi et al, 1987; Sheabar andYannai,
1989).
5Grando SA, George PM, Dahl MV, Conti-Tronconi BM: Antibody
against keratinocyte nicotinic acetylcholine receptor in patient with coex-
istent pemphigus foliaceus, myasthenia gravis and thymoma. J Invest Der-
matol 102:609, abstr. #511, 1994
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et al, 1990; Rinner et al, 1990), the thymus expresses both the
‘‘muscle’’ a1 and the ‘‘neuronal’’ or ‘‘epithelial’’ a3, a5, a7, and b4
types of nAChR subunits (Wheatley et al, 1992; Navaneetham et
al, 1997; Mihovilovic and Butterworth-Robinette, 2001).
Therefore, these two autoimmune diseases might develop as a
result of autoimmune responses triggered by autosensitization
against the AChR expressed by the thymus. In myasthenia, such
sensitization would focus on the AChR expressed by myocytes;
in pemphigus, on the AChR expressed by keratinocytes. On the
basis of this model, only those patients with thymoma/thymitis
would be expected to develop a second or third disease whose
antibodies are directed toward the epitope of thymic AChR
shared by the AChR expressed in the muscle or skin. Future
studies are needed to determine whether the keratinocyte self
antigens targeted by autoantibodies in pemphigus patients with
MG are the same as those targeted in patients with pemphigus
without thymoma/thymitis and/or myasthenia.
CHOLINERGIC SIDE EFFECTS OF DRUGS USED TO
TREAT PEMPHIGUS
The enigma of pemphigus stems from the fact that the doses of
GS required to stop blistering, as well as to sustain remission in
many patients, are usually much higher compared to those ordi-
narily used to control other autoimmune diseases (Myles and
Daly, 1974). In pemphigus, GS may work by (1) inhibiting anti-
body synthesis; (2) suppressing in£ammation, especially eosino-
philic spongiosis; and (3) stopping acantholysis via direct
pharmacologic e¡ect on keratinocyte, given that the addition of
GS to skin organ cultures treated with pemphigus antibodies pre-
vents pemphigus IgG^induced acantholysis (Swanson and Dahl,
1983; Je¡es et al, 1984).The last of the three mechanisms just listed,
reported independently by two di¡erent groups, deserves parti-
cular attention because the use of very large doses of methylpred-
nisolone (‘‘pulse therapy’’) suppresses pemphigus in patients
within 48 hours (Werth, 1996), and it is believed that the thera-
peutic e¡ect is mediated by a direct pharmacologic e¡ect of GS
on keratinocytes (Hashimoto et al, 1984).We recently reported that
PV IgG and methylprednisolone exhibit reciprocal e¡ects on the
transcription, translation, and phosphorylation of keratinocyte
adhesion molecules.6 Methylprednisolone upregulated transcrip-
tion of the genes encoding desmoglein 3, desmocollins, plakophi-
lin, E-cadherin, p-cadherin, a-catenin, several protein phospha-
tases, protease inhibitors, and lipocortins, and also suppressed
PVIgG-induced phosphorylation of adhesion molecules. There-
fore, GS may block PVIgG-induced acantholysis via a complex
of intracellular genomic and nongenomic events, some of which
are also involved in mediating signaling from keratinocyte
AChR. Further elucidation of the mechanisms underlying the
therapeutic activity of GS and other drugs that have been or are
successfully used to treat pemphigus may shed light on the phar-
macologic mechanisms mediating pemphigus IgG^induced
acantholysis.
Nonsteroidal treatments of pemphigus reported to date include
the following drugs (in chronological order): quinine and strych-
nine (reviewed in Kartamyshev, 1949), organic arsenic compounds
(Oppenheim, 1927), suramin (also known as germanin or ne-
phuride) (Veiel, 1931), vitamin D (Ludy and DeValin, 1932), meth-
otrexate (Lever and Goldberg, 1969), azathioprine (Wol¡ and
Schreiner, 1969), cyclophosophamide (Krain et al, 1972), gold (Pen-
neys et al, 1973), dapsone (Haim and Friedman-Birnbaum, 1978),
heparin (Mashkilleyson, 1985), cyclosporine (Balda and Rosenz-
weig, 1986), quercetin and doxycyline (Grando, 1988), aprotinin
and e-aminocaproic acid (Grando, 1992), nicotinamide and tetra-
cycline (Cha⁄ns et al, 1993), minocycline (Sawai et al, 1995),
p-aminomethylbenzoic acid (Dobrev et al, 1996), mycophenolate
mofetil (Enk and Knop, 1997), and tranilast (Miyamoto andTaka-
hashi, 1997). Surprisingly, a single mechanism of action common
for GS and many of the above listed nonsteroid drugs is choliner-
gic activity (Table 2). Is this a mere coincidence, or does the phar-
macologic modulation of keratinocyte ACh axis provide a
common denominator of antiacantholytic action of these drugs?
The post-corticosteroid era in the treatment of pemphigus:
it is possible The results of the clinical trial of Mestinon
suggest that nonsteroidal treatment of PV patients can be
achieved by pharmacologically stimulating keratinocyte cell-to-
cell adhesion through the keratinocyte ACh axis. Future studies
in this direction will create an opportunity for pemphigus
patients to obtain safer treatment of their disabling condition. A
successful GS-free treatment regimen should be able to e⁄ciently
block the intracellular signaling elicited by pemphigus antibody
binding to keratinocytes. Both an immediate and a more distant
solution to this problem should be sought. An immediate
solution will be to identify a pharmacological substitute for, or
an adjunct to, GS that can e⁄ciently control acantholysis. A
more distant solution will be to prevent acantholysis by
inhibiting synthesis of disease-causing pemphigus antibodies. In
addition to their use as a tolerogen for T cell tolerization in the
future, the sequences of the pathogenic epitopes of self antigens
can be used for ex-vivo selective immunoadsorption of disease-
causing pemphigus antibodies from patients’ blood. Thus,
successful development of nonsteroidal treatment of pemphigus
will animate patient management, as shown in Fig. 2.
This work was supported by a research grant from the Robert Leet & Clara Guthrie
PattersonTrust and by the International Pemphigus Research Fund.
REFERENCES
Akaike A, Ikeda SR, Brookes N, Pascuzzo GJ, Rickett DL, Albuquerque EX: The
nature of the interactions of pyridostigmine with the nicotinic acetylcholine
receptor-ionic channel complex. II. Patch clamp studies. Mol Pharmacol 25:102^
112, 1984
Albuquerque EX, Akaike A, Shaw KP, Rickett DL: The interaction of anticholines-
terase agents with the acetylcholine receptor-ionic channel complex. Fund Appl
Toxicol 4:27^S33, 1984
Amagai M, Karpati S, Prussick R, Klaus-Kovtun V, Stanley JR: Autoantibodies
against the amino-terminal cadherin-like binding domain of pemphigus vul-
garis antigen are pathogenic. J Clin Invest 90:919^926, 1992
Anadon A, Martinez-Larranaga MR: An inhibitory action of tetracyclines on gui-
nea-pig myenteric plexus. Arch Pharmacol 335:200^203, 1987
Aoyama Y, Owada MK, Kitajima Y: A pathogenic autoantibody, pemphigus vul-
garis-IgG, induces phosphorylation of desmoglein 3, and its dissociation from
plakoglobin in cultured keratinocytes. Eur J Immunol 29:2233^2240, 1999
Arredondo J, Hall LL, Ndoye A, ChernyavskyAI, Jolkovsky DL, Grando SA: Mus-
carinic acetylcholine receptors regulating cell cycle progression are expressed in
human gingival keratinocytes. J Periodont Res 38:79^89, 2003
Arteaga LA, Prisayanh PS,Warren SJ, Liu Z, Diaz LA, Lin MS: A subset of pemphi-
gus foliaceus patients exhibits pathogenic autoantibodies against both desmo-
glein-1 and desmoglein-3. J Invest Dermatol 118:806^811, 2002
Balda BR, Rosenzweig D: Cyclosporin A in the treatment of pemphigus foliaceus
and pemphigus erythematosus (In German). Hautarzt 37:454^457, 1986
Ben-Baruch G, Egozi Y, KloogY, Mashiach S, Sokolovsky M: Altered ontogenesis of
muscarinic cholinergic receptor in mouse brain: E¡ect of L-thyroxine and be-
tamethasone. Endocrinology 109:235^239, 1981
Beutner EH, Chorzelski TP, Jablonska S: Immuno£uorescence tests. Clinical signi¢-
cance of sera and skin in bullous diseases. Int J Dermatol 24:405^421, 1985
Beutner EH, Pelton S, Hashimoto T, et al: A nonfatal case and 2 fatal cases of para-
neoplastic pemphigus: Can a complement indirect immuno£uorescent test
help to identify fatal ‘group A’ paraneoplastic pemphigus cases? J Am Acad Der-
matol 47:841^851, 2002
Bouzat CB, Barrantes FJ: Acute exposure of nicotinic acetylcholine receptors to the
synthetic glucocorticoid dexamethasone alters single-channel gating proper-
ties. Mol Neuropharmacol 3:109^116, 1993
Braun S, Askanas V, EngelWK, Ibrahim EN: Long-term treatment with glucocorti-
coids increases synthesis and stability of junctional acetylcholine receptors on
innervated cultured human muscle. J Neurochem 60:1929^1935, 1993
6Nguyen VT, Arredondo J, Chernyavsky A, Pittelkow MR, KitajimaY,
Grando SA: Pemphigus vulgaris IgG (PVIgG) and a corticosteroid exhibit
reciprocal e¡ects on keratinocyte adhesion molecules. J Invest Dermatol
119:227, abstr. #116, 2002
PEMPHIGUS TREATMENT: NEWAPPROACHES 89VOL. 9, NO. 1 JANUARY 2004
Brenner S,Tur E, Shapiro J, et al: Pemphigus vulgaris: Environmental factors. Occu-
pational, behavioral, medical, and qualitative food frequency questionnaire. Int
J Dermatol 40:562^569, 2001
Carson PJ, Hameed A, Ahmed AR: In£uence of treatment on the clinical course of
pemphigus vulgaris. J Am Acad Dermatol 34:645^652, 1996
Cha⁄ns ML, Collison D, Fivenson DP:Treatment of pemphigus and linear IgA der-
matosis with nicotinamide and tetracycline: a review of 13 cases. J Am Acad
Dermatol 28:998^1000, 1993
Chasapakis G, Augustaki O, Kekis N, Philippou P, Moraitis H, Floras A, Makkous
A: The in£uence of the kallikrein-trypsin inactivator trasylol on the serum
cholinesterase. Br J Anaesth 40:456^458, 1993
Chen S, Inoue R, ItoY: Pharmacological characterization of muscarinic receptor-ac-
tivated cation channels in guinea-pig ileum. Br J Pharmacol 109:793^801, 1993
Conti-Tronconi BM, McLane KE, Raftery MA, Grando SA, Protti MP: The nico-
tinic acetylcholine receptor structure and autoimmune pathology. Crit Rev Bio-
chem Mol Biol 29:69^123, 1994
Dobrev H, Popova L,Vlashev D: Proteinase inhibitors and pemphigus vulgaris. An
in vitro and in vivo study. Arch Derm Res 288:648^655, 1996
Elgoyhen AB, Johnson DS, Boulter J,Vetter DE, Heinemann S: a9: An acetylcholine
receptor with novel pharmacological properties expressed in rat cochlear hair
cells. Cell 79:705^715, 1994
Engel AG, Lindstrom JM, Lambert EH, Lennon VA: Ultrastructural localization of
the acetylcholine receptor in myasthenia gravis and in its experimental auto-
immune model. Neurology 27:307^315, 1977
Enk AH, Knop J: Treatment of pemphigus vulgaris with mycophenolate mofetil.
Lancet 350:494, 1997
Esaki C, Seishima M,Yamada T, Osada K, KitajimaY: Pharmacologic evidence for
involvement of phospholipase C in pemphigus IgG-induced inositol 1,4,5-tri-
sphosphate generation, intracellular calcium increase, and plasminogen activa-
tor secretion in DJM-1 cells, a squamous cell carcinoma line. J Invest Dermatol
105:329^333, 1995
Esqui¢no AI, Selgas L, MaggioreVD, Castrillon PO, Cardinali DP: Diurnal changes
in cyclosporine e¡ect on ornithine decarboxylase and noradrenergic and cho-
linergic activities in submaxillary lymph nodes. Eur J Pharmacol 319:181^189,
1997
Fonseca MI, Lunt GG, Aguilar JS: Inhibition of muscarinic cholinergic receptors by
disul¢de reducing agents and arsenicals. Di¡erential e¡ect on locust and rat.
Biochem Pharm 41:735^742, 1991
Fontaine J, Fang ZY, Berkenboom G, Famaey JP: E¡ects of aurano¢n on endothe-
lium dependent contractions in isolated rat aorta. Agents Actions Suppl 32:83^87,
1991
Grando SA: Glukhen’kii BT, Romanenko AB: Role of endogenous proteinases and
their inhibitors in the pathogenesis of pemphigus vulgaris (In Russian).Vestn
Dermatol Venerol 8:4^7, 1987
Grando SA: Combined immunosuppressive therapy of autoimmune bullous derma-
toses (In Russian). Sov Med 2:113^115, 1988
Grando SA: Decompensation in proteinase-inhibitor system and application of pro-
teinase inhibitors in pemphigus and pemphigoid. J Dermatol Sci 4:95^97, 1992
Grando SA: Biological functions of keratinocyte cholinergic receptors. J Invest Der-
matol Symp ProcThe 2:41^48, 1997
Grando SA: Autoimmunity to keratinocyte acetylcholine receptors in pemphigus.
Dermatology 201:290^295, 2000
Grando SA, Crosby AM, Zelickson BD, Dahl MV: Agarose gel keratinocyte out-
growth system as a model of skin re-epithelization: Requirement of endogen-
ous acetylcholine for outgrowth initiation. J Invest Dermatol 101:804^810, 1993
Grando SA, Dahl MV: Activation of keratinocyte muscarinic acetylcholine receptors
reverses pemphigus acantholysis. J EurAcad Dermatol Venereol 2:72^86, 1993
Grando SA, Drannik GN, Glukhenky BT, Kostromin AP, Romanenko AB, Chayun
OA, ChernyavskyAI: Clinical and laboratory evaluation of hemocarboadsorp-
tion in autoimmune bullous dermatoses. Int J Arti£ Org 13:181^188, 1990
Grando SA, Glukhenky BT, Drannik GN, Epshtein EV, Kostromin AP, Korostash
TA: Mediators of in£ammation in blister £uids from patients with pemphigus
vulgaris and bullous pemphigoid. Arch Dermatol 125:925^930, 1989a
Grando SA, Glukhenky BT, Drannik GN, Kostromin AP, Boiko Y, Senyuk OF:
Autoreactive cytotoxicT lymphocytes in pemphigus and pemphigoid. Autoim-
munity 3:247^26, 1989b
Grando SA, Glukhenky BT, Drannik GN, Kostromin AP, Chernyavsky AI: Cyto-
toxic proteases in blister £uid of pemphigus and pemphigoid patients. Int JTiss
Reac 11:195^20, 1989c
Grando SA, Glukhenky BT, Drannik GN, Kostromin AP, Romanenko AB: The ef-
fect of experimental hemocarbo¢ltration upon activity of mononuclear cells
from normal and autoimmune patients. Immunology 66:138^142, 1989d
Grando SA, Glukhenky BT, Romanenko AB, Demidov SV: Pemphigus antibody-
induced intercellular separation of cultivated murine epidermocytes is accom-
panied by change in ratio of intraepidermocytic cAMP/cGMP.The IV Interna-
tional Congress of Cell Biology Ottawa, pp 69, 1988
Grando SA, Grando AA, Glukhenky BT, DoguzovV, NguyenVT, Holubar K: His-
tory and clinical signi¢cance of mechanical symptoms in blistering derma-
toses: A reappraisal. J Am Acad Dermatol 48:86^92, 2003
Grando SA, Horton RM, Mauro TM, Kist DA, Lee TX, Dahl MV: Activation of
keratinocyte nicotinic cholinergic receptors stimulates calcium in£ux and en-
hances cell di¡erentiation. J Invest Dermatol 107:412^418, 1996
Grando SA, Horton RM, Pereira EFR, Diethelm-Okita BM, George PM, Albu-
querque EX, Conti-Fine BM: A nicotinic acetylcholine receptor regulating
cell adhesion and motility is expressed in human keratinocytes. J Invest Derma-
tol 105:774^781, 1995a
Grando SA, Pittelkow MR, Shultz LD, Dmochowski M, Nguyen VT: Pemphigus:
An unfolding story. J Invest Dermatol 117:990^995, 2001
Grando SA, Zelickson BD, Kist DA, et al: Keratinocyte muscarinic acetylcholine re-
ceptors. Immunolocalization and partial characterization. J Invest Dermatol
104:95^100, 1995b
Haim S, Friedman-Birnbaum R: Dapsone in the treatment of pemphigus vulgaris.
Dermatologica 156:120^123, 1978
Hashimoto K, Singer K, Lazarus GS: The e¡ect of corticosteroids, dapsone and gold
upon plasminogen activator synthesis and secretion by human epidermal cells
cultured with pemphigus antibody. Br J Dermatol 110:293^297, 1984
Henning RH, Nelemans A, Scaf AH, Van Eekeren J, Agoston S, Den Hertog A:
Suramin reverses non-depolarizing neuromuscular blockade in rat diaphragm.
Eur J Pharmacol 216:73^79, 1992
Herbst A, Bystryn JC: Patterns of remission in pemphigus vulgaris. J Am Acad Der-
matol 42:422^388, 1994
Higashida H, Egorova A, Hoshi N, Noda: Streptozotocin, an inducer of NADþ
decrease, attenuates M-potassium current inhibition by ATP, bradykinin, an-
giotensin II, endothelin 1 and acetylcholine in NG108-15 cells. FEBS Lett
379:236^238, 1996
Higashida H, Robbins J, Egorova A, Noda M, Taketo M, Ishizaka N, Takasawa S,
Okamoto H, Brown DA: Nicotinamide-adenine dinucleotide regulates mus-
carinic receptor-coupled Kþ (M) channels in rodent NG108-15 cells. J Physiol
482:317^323, 1995
Hoecker M,Waschulewski IH, Kern HF, Domagk KA, Schwarzho¡ R, Foelsch UR,
Schmidt WE: Cyclosporin A inhibits protein-kinase-C-mediated amylase re-
lease from isolated rat pancreatic acini. Digestion 55:380^388, 1994
Holubar K, Fellner MJ: Pemphigus and related diseases. In: Rook A, Parish C, Beare
JM (eds). Practical Management of the Dermatologic Patient. Philadelphia: J.B. Lip-
pincott, 1986; p 153^155
Hopf C, HochW: Heparin inhibits acetylcholine receptor aggregation at two distinct
steps in the agrin-induced pathway. Eur J Neurosci 9:1170^1177, 1997
Hortnagl H, Berger ML, Havelec L, Hornykiewicz O: Role of glucocorticoids in the
cholinergic degeneration in rat hippocampus induced by ethylcholine aziridi-
nium AF64A. J Neurosci 13:2939^2945, 1993
Inoue M, Kuriyama H: Glucocorticoids inhibit acetylcholine-induced current in
chroma⁄n cells. AmJ Physiol 257:C906^C912, 1989
al-Jafari AA, Duhaiman AS, Kamal MA: Inhibition of human acetylcholinesterase
by cyclophosphamide.Toxicology 96:1^6, 1995
Je¡es E, Kaplan RP, Ahmed AR: Acantholysis produced in vitro with pemphigus
serum. Hydrocortisone inhibits acantholysis, while dapsone and 6-mercapto-
purine do not inhibit acantholysis. J Clin Lab Immunol 4:359^363, 1984
Joly P,Thomine E, Gilbert D, et al: Overlapping distribution of autoantibody speci-
¢cities in paraneoplastic pemphigus and pemphigus vulgaris. J Invest Dermatol
103:65^72, 1994
Kamikawa Y: Inhibitory e¡ect of anti-allergic drugs on cholinergic and non-choli-
nergic neurotransmissions of guinea pig bronchial muscle in vitro. Ann Allergy
63:59^63, 1989
Kaplan RP, Callen JP: Pemphigus associated diseases and induced pemphigus. Clin
Dermatol 1:42^71, 1983
Kartamyshev AI: Pemphigus vulgaris. Chronic pemphigus. Clin Laboratory Essay (in
Russian), Kiev pp 9^14, 1949
Kaufman H,Vadasz C, Lajtha A: E¡ects of estradiol and dexamethasone on choline
acetyltransferase activity in various rat brain regions. Brain Res 453:389^392,
1988
Ke L, Lukas RJ: E¡ects of steroid exposure on ligand binding and functional activities
of diverse nicotinic acetylcholine receptor subtypes. J Neurochem 67:1100^1112, 1996
Kobayashi H,Yuyama A, Ishihara M, Matsusaka N: E¡ects of arsenic on cholinergic
parameters in brain in vitro. Neuropharmacology 26:1707^1713, 1987
Koeppen A, Klein J, Erb C, Loe¡elholz K: Acetylcholine release and choline avail-
ability in rat hippocampus: E¡ects of exogenous choline and nicotinamide. J
Pharmacol ExpTher 282:1139^1145, 1997
Koeppen A, Klein J, Schmidt BH,Van Der Staay F-J, Loe¡elholz K: E¡ects of nico-
tinamide on central cholinergic transmission and on spatial learning in rats.
Pharmacol Biochem Behav 53:783^790, 1996
Kowalczyk AP, Bornslaeger EA, Norvell SM, Palka HL, Green KJ: Desmosomes.
Intercellular adhesive junctions specialized for attachment of intermediate ¢la-
ments. Int Rev Cytol 185:237^302, 1999
Krain LS, Landau JW, Newcomer VD: Cyclophosphamide in the treatment of pem-
phigus vulgaris and bullous pemphigoid. Arch Dermatol 106:657^661, 1972
Lever WF, Goldberg HS: Treatment of pemphigus vulgaris with methotrexate. Arch
Dermatol 100:70^78, 1969
Lever WF, Schaumburg-Lever G: Immunosuppressants and prednisone in pemphi-
gus vulgaris: Therapeutic results obtained in 63 patients between 1961 and
1975. Arch Dermatol 113:1236^1241, 1977
LeverWF, Schaumburg-Lever G:Treatment of pemphigus vulgaris. Results obtained
in 84 patients between 1961 and 1982. Arch Dermatol 120:44^47, 1984
Ludy JB, DeValin CM: Viosterol in the treatment of pemphigus. Urol Cutan Rev
36:817, 1932
90 GRANDO JID SYMPOSIUM PROCEEDINGS
Lutterodt GD: Inhibition of gastrointestinal release of acetylcholine by quercetin as a
possible mode of action of Psidium guajava leaf extracts in the treatment of
acute diarrhoeal disease. J Ethnopharmacol 25:235^247, 1989
Lyubimov H, Goldshmit D, Michel B, Oron Y, Milner Y: Pemphigus: Identifying
the autoantigen and its possible induction of epidermal acantholysis via
Ca2þ signalling. Israel J Med Sci 31:42^48, 1995
Mareel MM, Behrens J, BirchmeierW, et al: Down-regulation of E-cadherin expres-
sion in Madin Darby canine kidney (MDCK) cells inside tumors of nude
mice. Int J Cancer 47:922^928, 1991
Marquardt DL, Motulsky HJ,Wasserman SI: Rat lung cholinergic receptor. Charac-
terization and regulation by corticosteroids. J Appl Physiol 53:731^736, 1982
Marx A, Osborn M, Tzartos S, et al: A striational muscle antigen and myasthenia
gravis-associated thymomas share an acetylcholine-receptor epitope. Dev Im-
munol 2:77^84, 1992
Mashkilleyson NA: Heparin action in pemphigus vulgaris. Clinical and immunolo-
gic studies. Acta DermVenereol 65:545^547, 1985
Maslinski W, Grabczewska E, Bartfai T, Ryzewski J: Muscarinic antagonist binding
to intact rat thymocytes. Acta Chem Scand 44:147^151, 1990
McKee PH, McClelland M, Sandford JC: Co-existence of pemphigus, anti-skeletal
muscle antibody and a retroperitoneal paraganglioma. Br J Dermatol 99:441^
445, 1978
Mehta JN, Martin AG: A case of pemphigus vulgaris improved by cigarette smok-
ing. Arch Dermatol 136:15^17, 2000
Mihovilovic M, Butterworth-Robinette J: Thymic epithelial cell line expresses tran-
scripts encoding a3, a5 and b4 subunits of acetylcholine receptors, responds to
cholinergic agents and expresses choline acetyl transferase. An in vitro system
to investigate thymic cholinergic mechanisms. J Neuroimmunol 117:58^67, 2001
Minker E, Blazso G: The e¡ect of alkylating agents on the synaptic transmission in
the frog’s isolated sympathetic ganglion. Eur J Drug Met Pharm 12:291^293, 1987
Miyamoto H,Takahashi I: Successful treatment of pemphigus vulgaris with predni-
solone and tranilast. Acta DermVenereol 77:87^88, 1997
Muller S, Stanley JR: Pemphigus: Pemphigus vulgaris and pemphigus foliaceus. In:
Wojnarowska F, Briggaman RA (eds). Management of Blistering Diseases. Lon-
don: Chapman & Hall Medical, 1990; p 43^61
Myles AB, Daly JR: Corticosteroid and ACTH treatment: principles and problems. 1974
Navaneetham D, Penn A, Howard J Jr, Conti-Fine BM: Expression of the a7 subunit
of the nicotinic acetylcholine receptor in normal and myasthenic human thy-
muses. Cell Mol Biol 43:433^442, 1997
Ndoye A, Buchli R, Greenberg B, et al: Identi¢cation and mapping of keratinocyte
muscarinic acetylcholine receptor subtypes in human epidermis. J Invest Derma-
tol 111:410^416, 1998
NguyenVT, Hall LL, Gallacher G, et al: Choline acetyltransferase, acetylcholinester-
ase, and nicotinic acetylcholine receptors of human gingival and esophageal
epithelia. J Dent Res 79:939^949, 2000a
Nguyen VT, Lee TX, Ndoye A, et al: The pathophysiological signi¢cance of non-
desmoglein targets of pemphigus autoimmunity. Pemphigus vulgaris and fo-
liaceus patients develop antibodies against keratinocyte cholinergic receptors.
Arch Dermatol 134:971^980, 1998
Nguyen VT, Ndoye A, Bassler KD, et al: Classi¢cation, clinical manifestations, and
immunopathological mechanisms of the epithelial variant of paraneoplastic
autoimmune multiorgan syndrome: A reappraisal of paraneoplastic pemphi-
gus. Arch Dermatol 137:193^206, 2001
NguyenVT, Ndoye A, Grando SA: Novel human a9 acetylcholine receptor regulat-
ing keratinocyte adhesion is targeted by pemphigus vulgaris autoimmunity.
AmJ Pathol 157:1377^1391, 2000b
Nguyen VT, Ndoye A, Grando SA: Pemphigus vulgaris antibody identi¢es pem-
phaxin: A novel keratinocyte annexin-like molecule binding acetylcholine. J
Biol Chem 275:29466^29476, 2000c
Nurowska E, Ruzzier F: Corticosterone modi¢es the murine muscle acetylcholine
receptor channel kinetics. Neuroreport 8:77^80, 1996
Ohlstein EH, Horohonich S: Selective inhibition of endothelium-dependent relaxa-
tion by gold-containing compounds. Pharmacology 38:93^100, 1989
Olianas MC, Onali P: Impairment of muscarinic stimulation of adenylyl cyclase by
heparin in rat olfactory bulb. Life Sci 61:515^522, 1997
Oppenheim M: Pemphigus chronicus serpiginosus. Z Haut Geschlecht 26:41, 1927
Osada K, Seishima M, KitajimaY: Pemphigus IgG activates and translocates protein
kinase C from the cytosol to the particulate/cytoskeleton fractions in human
keratinocytes. J Invest Dermatol 108:482^487, 1997
Parrish EP, Marston JE, Mattey DL, Measures HR, Venning R, Garrod DR: Size
heterogeneity, phosphorylation and transmembrane organisation of desmoso-
mal glycoproteins 2 and 3 (desmocollins) in MDCK cells. J Cell Sci 96:239^
248, 1990
Pascuzzo GJ, Akaike A, Maleque MA, Shaw KP, Aronstam RS, Rickett DL, Albu-
querque EX: The nature of the interactions of pyridostigmine with the nico-
tinic acetylcholine receptor-ionic channel complex. I. Agonist, desensitizing,
and binding properties. Mol Pharmacol 25:92^101, 1984
Pasdar M, Li Z, Chan H: Desmosome assembly and disassembly are regulated by
reversible protein phosphorylation in cultured epithelial cells. Cell Motil Cytos-
keleton 30:108^121, 1995
Penneys NS, EaglsteinWH, Indgin S, Frost P: Gold sodium thiomalate treatment of
pemphigus. Arch Dermatol 108:56^60, 1973
Peroutka SJ: Chemotherapeutic agents do not interact with neurotransmitter recep-
tors. Cancer Chemother Pharmacol 19:131^132, 1987
Porter RK, Scott JM, Brand MD: Choline transport into rat liver mitochondria.
Characterization and kinetics of a speci¢c transporter. J Biol Chem 267:14637^
14646, 1992
Rinner I, Porta S, Schauenstein K: Characterization of 3H-N-methylscopolamine
binding to intact rat thymocytes. Endocrinol Exp 24:125^132, 1990
Romanenko AV: The action of nicotinamide on neuromuscular transmission. Fizio-
logicheskii Zhurnal (Kiev) 33:51^56, 1987
Sawai T, Kitazawa K, Danno K, Sugie N, Machizuki T, Sugiura H, Uehara M: Pem-
phigus vegetans with oesophageal involvement. Successful treatment with
minocycline and nicotinamide. Br J Dermatol 132:668^670, 1995
Seishima M, Esaki C, Osada K, Mori S, Hashimoto T, KitajimaY: Pemphigus IgG,
but not bullous pemphigoid IgG, causes a transient increase in intracellular
calcium and inositol 1,4,5-triphosphate in DJM-1 cells, a squamous cell carci-
noma line. J Invest Dermatol 104:33^37, 1995
Sgard F, Charpantier E, Bertrand S, et al: A novel human nicotinic receptor subunit,
a10, that confers functionality to the a9-subunit. Mol Pharmacol 61:150^159,
2002
Sheabar FZ, Yannai S: In vitro e¡ects of cadmium and arsenite on glutathione per-
oxidase, aspartate and alanine aminotransferases, cholinesterase and glucose-6-
phosphate dehydrogenase activities in blood.Vet HumToxicol 31:528^531, 1989
Sherer Y, Bar-Dayan Y, Shoenfeld Y: Thymoma, thymic hyperplasia, thymectomy
and autoimmune diseases. Review. Int J Oncol 10:939^943, 1997
Small DH, Ismael Z, Chubb IW: Acetylcholinesterase exhibits trypsin-like and me-
talloexopeptidase-like activity in cleaving a model peptide. Neuroscience 21:991^
995, 1987
Ssieb JP, Milone M, Engel AG: E¡ects of the quinoline derivatives quinine, quini-
dine, and chloroquine on neuromuscular transmission. Brain Res 712:179^189,
1996
StappenbeckTS, Lamb JA, Corcoran CM, Green KJ: Phosphorylation of the desmo-
plakin COOH terminus negatively regulates its interaction with keratin inter-
mediate ¢lament networks. J Biol Chem 269:29351^29354, 1994
Stemm C, Thivolet J: Weaning of systemic steroid treatment in pemphigus. A
twelve-year retrospective study on 270 French patients. Eur J Dermatol 5:664^
670, 1995
Sterz R, Peper K, Simon J, Ebert JP, Edge M, Pagala M, Bradley RJ: Agonist and
blocking e¡ects of choline at the neuromuscular junction. Brain Res 385:99^114,
1986
Stoytcheva M, Zlatev R: Bioelectrocatalytical studies of the e¡ect of some pharma-
ceuticals on the acetylcholinesterase activity. Electroanalysis 8:676^679, 1996
Swanson DL, Dahl MV: Methylprednisolone inhibits pemphigus acantholysis in
skin cultures. J Invest Dermatol 81:258^260, 1983
Szonyi M, Csermely P, Sziklai I: Acetylcholine-induced phosphorylation in isolated
outer hair cells. Acta Otolaryngol 119:185^188, 1999
Talesa V, Principato GB, Giovannini E, Di Giovanni MV, Rosi G: Dimeric forms of
cholinesterase in Sipunculus-nudus. Eur J Biochem 215:267^275, 1993
Taylor P: Anticholinesterase agents. In: Gilman AG, Goodman LS, Rall TW, Murad
F (eds). Goodman and Gilman’s Pharmacological Basis of Therapeutics. New York:
Macmillan, 1985; p 110^127
Tria MA,Vantini G, Fiori MG, Rossi A: Choline acetyltransferase activity in murine
thymus. J Neurosci Res 31:380^386, 1992
Tzartos SJ, Seybold ME, Lindstrom JM: Speci¢cities of antibodies to acetylcholine
receptors in sera from myasthenia gravis patients measured by monoclonal
antibodies. Proc Natl Acad Sci USA 79:188^192, 1982
Ulus IH, MillingtonWR, Buyukuysal RL, Kiran: Choline as an agonist: Determi-
nation of its agonistic potency on cholinergic receptors. Biochem Pharm 37:2747^
2755, 1988
Veiel F: Die Behandlung des Pemphigus mit Germanin. Munchn Med Wchnschr
78:2047, 1931
Vilquin JT, Braun S, Labouret P, Zuber G,Tranchant C, Poindron P,Warter JM: Spe-
ci¢c e¡ect of corticoids on acetylcholine receptor expression in rat skeletal
muscle cell cultures. J Neurosci Res 31:285^293, 1992
Wang SZ, Edmundson R, Zhu SZ, El-Fakahany EE: Selective enhancement of an-
tagonist ligand binding at muscarinic M-2 receptors by heparin due to recep-
tor uncoupling. Eur J Pharmacol 296:113^118, 1996
Werth VP: Treatment of pemphigus vulgaris with brief, high-dose intravenous glu-
cocorticoids. Arch Dermatol 132:1435^1439, 1996
Wheatley LM, Urso D,Tumas K, Maltzman J, Loh E, Levinson AI: Molecular evi-
dence for the expression of nicotinic acetylcholine receptor alpha-chain in
mouse thymus. J Immunol 148:3105^3109, 1992
Winkelman RK, Sams WM Jr, Bohr DF: E¡ect of nicotinate ester, acetylcholine,
and other vasodilating agents on cutaneous and mesenteric vascular smooth
muscle. Circ Res 25:687^692, 1969
Wol¡ K, Schreiner E: Immunosuppressive therapy of pemphigus vulgaris. Prelimin-
ary results of azathioprine (Imuran) treatment (in German). Arch Klin Exp Der-
matol 235:63^77, 1969
Younus J, Ahmed AR: The relationship of pemphigus to neoplasia. J Am Acad Der-
matol 23:498^502, 1990
Zheng JQ, Felder M, Poo MM: Turning of nerve growth cones induced by neuro-
transmitters. Nature 368:140^144, 1994
PEMPHIGUS TREATMENT: NEWAPPROACHES 91VOL. 9, NO. 1 JANUARY 2004
